TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTCRYPTOMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTERTECHNOLOGY
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Wall Street Stock Market
Play
JIM CRAMER

Resilient Bull: Cramer's 'Mad Money' Recap (Wednesday 1/8/20)

  • By Scott Rutt
  • Jan 8, 2020 9:24 PM EST
PRESS RELEASES

Apellis And Sobi: The New England Journal Of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan To Eculizumab For PNH

  • By GlobeNewswire
  • Mar 17, 2021 5:48 PM EDT
PRESS RELEASES

Apellis Announces Two New Publications From The Positive Phase 2 FILLY Study Evaluating Pegcetacoplan In Geographic Atrophy

  • By GlobeNewswire
  • Mar 10, 2021 9:15 AM EST
PRESS RELEASES

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • By GlobeNewswire
  • Mar 5, 2021 4:05 PM EST
PRESS RELEASES

Apellis Provides Update On APL-9 For Severe COVID-19

  • By GlobeNewswire
  • Mar 4, 2021 4:05 PM EST
PRESS RELEASES

Apellis Pharmaceuticals To Present At Upcoming Investor Conferences

  • By GlobeNewswire
  • Feb 22, 2021 8:00 AM EST
PRESS RELEASES

Apellis Pharmaceuticals To Hold Fourth Quarter And Full Year 2020 Earnings Conference Call On February 25, 2021

  • By GlobeNewswire
  • Feb 18, 2021 4:05 PM EST
PRESS RELEASES

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • By GlobeNewswire
  • Feb 5, 2021 4:05 PM EST
PRESS RELEASES

Apellis Pharmaceuticals To Host Investor Event On Geographic Atrophy On January 28, 2021

  • By GlobeNewswire
  • Jan 21, 2021 7:00 AM EST
PRESS RELEASES

Apellis Pharmaceuticals To Present At The 39th Annual J.P. Morgan Healthcare Conference

  • By GlobeNewswire
  • Jan 5, 2021 7:00 AM EST
PRESS RELEASES

Apellis And Sobi Report Positive Top-line Results At 48 Weeks From The Phase 3 PEGASUS Study Of Pegcetacoplan In PNH

  • By GlobeNewswire
  • Dec 10, 2020 6:00 AM EST
PRESS RELEASES

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • By GlobeNewswire
  • Dec 4, 2020 4:05 PM EST
PRESS RELEASES

Apellis Pharmaceuticals To Present At The 2020 Evercore ISI HealthCONx Conference

  • By GlobeNewswire
  • Nov 30, 2020 7:00 AM EST
PRESS RELEASES

Apellis And Sobi Announce First Patient Dosed In Potentially Registrational ALS Study Of Pegcetacoplan

  • By GlobeNewswire
  • Nov 19, 2020 6:45 AM EST
PRESS RELEASES

Apellis Announces Late-Breaking Presentation Of Largest Retrospective Database Study In Geographic Atrophy (GA) At AAO 2020 Virtual

  • By GlobeNewswire
  • Nov 13, 2020 10:40 AM EST
PRESS RELEASES

Apellis Pharmaceuticals To Present At Upcoming Investor Conferences

  • By GlobeNewswire
  • Nov 11, 2020 7:00 AM EST
PRESS RELEASES

Apellis To Present New Data Supporting The Efficacy And Safety Of Pegcetacoplan In PNH At The American Society Of Hematology Annual Meeting

  • By GlobeNewswire
  • Nov 5, 2020 7:00 AM EST
PRESS RELEASES

Apellis To Present Positive Results From The Phase 2 DISCOVERY Study Of Pegcetacoplan In C3 Glomerulopathy (C3G) At ASN Kidney Week

  • By GlobeNewswire
  • Oct 9, 2020 10:14 AM EDT
PRESS RELEASES

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • By GlobeNewswire
  • Oct 7, 2020 4:05 PM EDT
PRESS RELEASES

Apellis Initiates Registrational Programs Of Pegcetacoplan In Patients With C3G / IC-MPGN And ALS, Rare Diseases With High Unmet Need

  • By GlobeNewswire
  • Oct 5, 2020 7:00 AM EDT
PRESS RELEASES

Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression Of Early Disease In Patients With Geographic Atrophy (GA)

  • By GlobeNewswire
  • Oct 3, 2020 11:05 AM EDT
PRESS RELEASES

Apellis Pharmaceuticals To Present At Stifel's 2020 Immunology And Inflammation Virtual Summit

  • By GlobeNewswire
  • Sep 24, 2020 4:05 PM EDT
PRESS RELEASES

Apellis Announces Late-Breaking Presentation Of Targeted C3 Therapy Pegcetacoplan In Patients With Geographic Atrophy (GA) At EURETINA 2020

  • By GlobeNewswire
  • Sep 21, 2020 4:05 PM EDT
PRESS RELEASES

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • By GlobeNewswire
  • Sep 4, 2020 4:05 PM EDT
PRESS RELEASES

Apellis Pharmaceuticals To Present At Upcoming Investor Conferences

  • By GlobeNewswire
  • Sep 2, 2020 7:00 AM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.